March 26, 2018 / 10:39 AM / a month ago

BRIEF-Fennec Says Phase 3 SIOPEL 6 Study Met Primary Endpoint

March 26 (Reuters) - Fennec Pharmaceuticals Inc:

* FENNEC PROVIDES BUSINESS UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2017 FINANCIAL RESULTS

* PHASE 3 SIOPEL 6 STUDY MET PRIMARY ENDPOINT

* FENNEC - SIOPEL 6 STUDY SHOWED ADDITION OF STS SIGNIFICANTLY REDUCES INCIDENCE OF CISPLATIN-INDUCED HEARING LOSS WITHOUT EVIDENCE OF TUMOR PROTECTION

* QTRLY ‍LOSS PER SHARE $0.15​

* FENNEC - ‍BELIEVES CASH & CASH EQUIVALENTS ON HAND AS OF DEC 31, 2017 WILL BE SUFFICIENT TO FUND PLANNED COMMERCIAL LAUNCH OF PEDMARK (TM) IN H2 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below